Impact of<i>ompk36</i>genotype and KPC subtype on the<i>in vitro</i>activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing<i>K. pneumoniae</i>clinical isolates
JAC-antimicrobial resistance